http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3916088-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d0f93a136a676c6b153808b7c56e599 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68f0fa6a3ba9a5efb89ecdae98e9790b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-23 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-22069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3916088-A1 |
| titleOfInvention | Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents |
| abstract | In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, several projects have been launched around the world to understand the viral evolution and the pathophysiological consequences of the infection in order to identify therapeutic targets and to implement innovative therapies. In particular, the 3C-like proteinase (3CLpro) of the severe acute respiratory syndrome coronavirus (SARS-CoV) plays a vital role in virus maturation and is proposed to be a key target for drug design against SARS. The present invention relates to fusion proteins comprising the SARS-CoV-2 3CLpro catalytic domain and their uses for screening anti-SARS-Cov-2 agents. |
| priorityDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 188.